Table 3.
The clinicopathological characters of CRC patients.
| Count | % | |
|---|---|---|
| Total | 43 | 100 |
| Age | ||
| ⩽45 y | 22 | 51.1 |
| >45 y | 21 | 48.8 |
| Sex | ||
| Female | 19 | 44.2 |
| Male | 24 | 55.8 |
| Smoking | ||
| Non smoker | 28 | 65.1 |
| Smoker | 15 | 34.9 |
| Baseline CEA | ||
| Normal | 30 | 69.8 |
| High | 13 | 30.2 |
| Baseline CA19.9 | ||
| Normal | 28 | 65.1 |
| High | 15 | 34.9 |
| Site of tumour | ||
| Non specified | 5 | 11.6 |
| Right colon | 11 | 25.6 |
| Left colon | 10 | 23.3 |
| Rectum | 17 | 39.5 |
| Pathology | ||
| Adenocarcinoma | 33 | 76.7 |
| Mucinous | 10 | 23.3 |
| T | ||
| T2 | 6 | 14.0 |
| T3 | 26 | 60.5 |
| T4 | 11 | 25.6 |
| N | ||
| Negative | 27 | 62.8 |
| Positive | 16 | 37.2 |
| M | ||
| Negative | 23 | 53.5 |
| Positive | 20 | 46.5 |
| Stage | ||
| II | 7 | 16.3 |
| III | 16 | 37.2 |
| IV | 20 | 46.5 |
| First line FP therapy | ||
| Single (Capecitabine) | 7 | 16.3 |
| Combined (+Oxaliplatin) | 36 | 83.7 |
Data presented as count and percentage of 43 CRC patients at different clinicopathological subgroups.
Abbreviations: CEA, carcinoembyonic antigen; CA19.9, carbohydrate antigen 19.9; T, tumour burden; N, lymph node; M, metastasis.